Other languages Johnson & Johnson Swiss Exchange

Equities

JNJ

US4781601046

Real-time Estimate Cboe BZX Other stock markets 12:58:18 21/06/2024 BST			5-day change	1st Jan Change
147.5 ^USD	+8.46%		-0.73%	0.00%

01:37pm	Johnson & Johnson Completes Acquisition of Proteologix	MT
01:36pm	Johnson & Johnson Completes Acquisition of Proteologix	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Johnson & Johnson Completes Acquisition of Proteologix	12:37pm
Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	06-20
Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease	06-20
J&J : lance un écosystème numérique ouvert et sécurisé	06-20
J&J : des résultats prometteurs dans la maladie de Crohn	06-20
Johnson & Johnson Says Phase 3 Trial of Tremfya to Treat Crohn's Disease Met Co-Primary Endpoints	06-20
Johnson & Johnson Announces Positive Topline Results from the Pivotal Phase 3 GRAVITI Investigational Study of TREMFYA® Subcutaneous (SC) Induction Therapy in Adult Patients with Moderate to Severe Active Crohn's Disease	06-20
J&J : sollicite la FDA dans le cancer du poumon	06-17
Johnson & Johnson Seeks US FDA Approval for Subcutaneous Amivantamab for Certain Patients With Non-Small Cell Lung Cancer	06-17
Johnson & Johnson Submits Subcutaneous Amivantamab Biologics License Application to U.S. FDA for Patients with EGFR-Mutated Non-Small Cell Lung Cancer	06-17
J&J : résultat positif dans la maladie de Sjögren	06-17
Johnson & Johnson's Potential Sjogren's Treatment Shows Improvement in Meeting Clinical Trial Endpoints	06-17
Johnson & Johnson Announces Late-Breaking Results Show nipocalimab Significantly Improves Sjögren's Disease Activity in A Phase 2 Study	06-15
EU regulator mandates label updates on CAR-T cancer therapies	06-14
J&J : essai encourageant dans le myélome multiple récidivant	06-14
J&J : les promesses de l'ibrutinib dans la LLC	06-14
J&J : résultats prometteurs pour Imbruvica dans la leucémie	06-14
Johnson & Johnson Reports Positive Long-Term Results for Talvey in Multiple Myeloma Study	06-14
Johnson & Johnson Announces TALVEY® (Talquetamab-Tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma	06-14
High-risk health workers can get routine Ebola vaccine, Gavi says	06-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm